Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing
23 Maio 2022 - 11:15AM
Elevar Therapeutics, Inc., a fully integrated biopharmaceutical
company dedicated to elevating treatment experiences and outcomes
for patients who have limited or inadequate therapeutic options,
today announced the hiring of Paul Friel as chief commercial
officer. Friel has more than 30 years’ experience in the
pharmaceutical industry, including leadership positions in
multinational corporations and biotech companies.
The company also named Dr. Michael Palucki, a pharmaceutical
industry veteran with 25 years of experience, as vice president of
manufacturing. Palucki has broad pharmaceutical knowledge with
direct experience in driving strategy and operational excellence
spanning drug discovery, drug development, regulatory filing,
product launch, commercialization and lifecycle management.
“Paul Friel and Dr. Michael Palucki are deeply qualified
biopharmaceutical leaders with proven track records and a keen
understanding of what it takes to drive product approvals and
launches in the U.S.,” said Dr. Saeho Chong, chief executive
officer of Elevar. “This is a critical time for Elevar and their
skill sets will enable us to realize our commercial objectives and
deliver on our commitment to fulfill the unmet needs of cancer
patients who are awaiting new therapeutic options. We are thrilled
to have them join our team.”
Friel most recently served as chief commercial officer at Beyond
Spring, Inc. (NASDAQ: BYSI), a global, clinical-stage
biopharmaceutical company. Previously, he served in roles of
increasing responsibility and leadership at pharmaceutical company
TAP/Takeda, including president and general manager at Takeda
Canada.
Friel has launched more than 20 products during his career,
including five that achieved more than $1 billion in sales. He also
held early leadership positions in five start-ups and led business
development for several large transitions and capital raises. He
holds an MBA from the University of Kansas and a Bachelor of
Science degree in business administration from Kansas State
University.
Palucki most recently served as executive director, CMC product
development and team leader for Venatorx Pharmaceuticals, Inc., a
private company focused on the discovery and development of novel
anti-infectives to treat multi-drug-resistant bacterial infections
and hard-to-treat viral infections. Prior to that, Palucki worked
at Merck & Co. in various roles including small molecule API
development leader, director CMC integrated development and supply
leader, and director, portfolio and product development lead for
mature brands.
Palucki was a National Institutes of Health Postdoctoral Fellow
at Massachusetts Institute of Technology. He holds a Doctor of
Philosophy, Organic Chemistry degree from Harvard University and a
Bachelor of Science degree from California State University of
Fullerton. Palucki has authored/co-authored 43 publications and 12
patents.
About Elevar Therapeutics
Elevar Therapeutics is a rapidly growing, fully integrated
biopharmaceutical company built on the promise of elevating
treatment experiences and outcomes for patients who have limited or
inadequate therapeutic options. Elevar’s lead proprietary drug
candidates include rivoceranib (apatinib) and Apealea® (paclitaxel
micellar). Rivoceranib is the first small-molecule tyrosine kinase
inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014).
It has been granted Orphan Drug designation in the U.S., Europe and
South Korea and has been clinically tested in over 1,000 patients
worldwide in numerous cancer indications. Apealea® (paclitaxel
micellar) is a non-Cremophor EL based formulation of paclitaxel
that received marketing authorization by the European Commission in
November 2018, making it Europe’s first non-Cremophor EL
formulation of paclitaxel approved for use in ovarian cancer.
Elevar Therapeutics has offices in Utah, California and South
Korea, and additional information is available at
www.elevartherapeutics.com.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6e6f9791-946b-4854-aa27-85a7df4ff266
Contact:
Jennifer Leckstrom
(215) 681-0770
jleckstrom@rosecomm.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024